Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer

Next Previous
Search
Trial Profile

A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 20 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bintrafusp alfa (Primary) ; Cisplatin; Gemcitabine
  • Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Periampullary cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms INTR@PID BTC 055
  • Sponsors EMD Serono Research & Development Institute; Merck KGaA

    • Most Recent Events

    • 26 Oct 2023 Status changed from completed to discontinued.
    • 14 Nov 2022 Status changed from active, no longer recruiting to completed.
    • 06 Oct 2022 This trial has been completed in Poland, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top